BusinessActinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-ABy Nasdaq OMXMay 24, 2017, 1:26 PM UTC
BusinessActinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha TherapyBy Nasdaq OMXMay 23, 2017, 11:32 AM UTC
BusinessActinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha TherapyBy Nasdaq OMXMay 23, 2017, 11:32 AM UTC
BusinessActinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha TherapyBy Nasdaq OMXMay 23, 2017, 11:32 AM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory BoardBy Nasdaq OMXMay 17, 2017, 11:01 AM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory BoardBy Nasdaq OMXMay 17, 2017, 11:01 AM UTC
BusinessActinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-BBy Nasdaq OMXMay 10, 2017, 11:01 AM UTC
BusinessActinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-BBy Nasdaq OMXMay 10, 2017, 11:01 AM UTC